Reuters logo
BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse
November 27, 2017 / 11:55 AM / in 14 days

BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse

Nov 27 (Reuters) - Catalyst Pharmaceuticals Inc:

* CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME

* CATALYST PHARMACEUTICALS INC - ‍TREATMENT WITH FIRDAPSE ACHIEVED STATISTICAL SIGNIFICANCE FOR CO-PRIMARY ENDPOINTS AND SECONDARY ENDPOINT​

* CATALYST PHARMACEUTICALS INC - ‍POSITIVE RESULTS TO SUPPORT PLANNED NDA SUBMISSION IN Q1 OF 2018​

* CATALYST PHARMACEUTICALS INC - ‍FIRDAPSE WAS SAFE AND WELL TOLERATED BY PATIENTS IN TRIAL​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below